Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nintedanib and Pirfenidone DDI in IPF
NCT02606877Phase 4Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Apr 2016
- Primary completion
- Mar 2017
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, open-label trial of nintedanib in idiopathic pulmonary fibrosis (IPF) (2 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Area Under the Concentration-time Curve of the Nintedanib in Plasma Over the Time Interval 0 to the Last Quantifiable Data Point, Maximum Measured Concentration of Nintedanib in Plasma After Single Dose Administration and 2 more. Started Apr 2016; status: completed.
02
Drugs
nintedanib
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT02606877.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02606877.